

Human SIRP α Monoclonal Antibody

Catalog No.: YR0021

Basic Information

Molecular Weight

150 kDa

Endotoxin

<1EU/mg (<0.001EU/ μ g) Determined by LAL gel clotting assay

Sterility

0.2 μ m filtration

Aggregation

<5% Determined by SECP

Purity

>95% Determined by SDS-PAGE

Background

Anzurstobart (CC-95251; BMS-986351) is a high-affinity, fully human monoclonal anti-SIRP α antibody that blocks the binding of CD47 to SIRP α . Anzurstobart enhances macrophage phagocytic activity against DLBCL cell lines in co-culture models when combined with the antibody Rituximab (HY-P9913). Anzurstobart has the potential for solid and hematologic malignancies research.

Reported Applications

ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways

Immunogen Information

Clone

Anzurstobart Biosimilar

Isotype

Human IgG1 kappa

Immunogen

Recommended Isotype Control(s)

Recommended Dilution Buffer

1 \times PBS pH 7.0

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Product Information

Production

Purified from cell culture supernatant in an animal-free facility


Purification

Protein A or G purification

Storage

2 - 8°C for up to 4 weeks and -80°C for long term storage (Avoid repeated freezing and thawing)

Validation Data



Human SIRPα ELISA Standard Curve. Direct ELISA binding curve demonstrating the recognition of Human Anti-Human SIRPα (Research Grade Anzurstobat Biosimilar) Monoclonal Antibody to SIRPα. The target protein was coated onto the microplate well surface, followed by binding of the antibody. Neutravidin HRP conjugate was used for detection.